Answers are grounded in this paper and cite their sources.
Explores AI-guided precision drug repurposing in relapsed cancers, indicating personalized treatment strategies.
e15117 Background: Introduction: Relapsed, refractory & metastatic cancers (RRM) are resistant to treatment due to extreme inter-patient heterogeneity & clinical limitations of treatment paradigms [1]. COSMIC mutational signatures capture underlying mutagenic pathways & provide a biologically integrated treatment framework that transcends single-gene alterations [2]. We hypothesized that integrating COSMIC signatures with artificial-intelligence (AI) algorithms could enable clinically actionable, single-patient precision drug repurposing in RRM [3]. Blast-crisis chronic myeloid leukemia (BC-CML) a genomically unstable & fatal disease was used as a proof-of-concept example [4]. Methods: Whole-exome sequencing was performed & COSMIC mutational signatures were extracted using SigProfilerExtractor to quantify dominant mutational processes at individual-patient resolution [1,5]. Unsupervised machine learning identified biologically coherent mutational signatures in each patient [3]. AI-guided drug prioritization was performed using PanDrugs, integrating mutations, signatures, and pharmacogenomic evidence to generate patient-specific, clinically actionable drug rankings [2]. Results: Each BC-CML patient exhibited a unique COSMIC signature profile, reflecting distinct biological drivers of leukemic progression and therapeutic vulnerability. Signature-defined biology mapped patients to hallmark pathways (Table). AI-based integration prioritized distinct repurposable FDA/EMA-approved therapies for each patient. No two patients shared an identical therapeutic profile, demonstrating true N-of-1 precision beyond cohort- or cluster-level classification. Conclusions: Discussion:This is a first-in-class, single-patient precision oncology framework shifting therapeutic decision-making from static mutations to dynamic mutational processes [1,6]. Using BC-CML as a model, this strategy is broadly applicable to RRM enabling rational drug repurposing when standard therapies fail supporting real-time, patient-level clinical decision-making [4,7]. References 1: Bobo M, et al. Int J Infect Dis. Jan 2026 2: Zhang L, et al. NPJ Precis Oncol. 2025 Dec 20 3: Li W et al. Discov Oncol 2026 Jan 12 4: Bhat M. Exp Cell Res. 2026 Feb 15 5: Ochi Y et al. Nat Commun. 2021 6: Wan Z. Adv Sci. 2025 7: Noor WD et al. Expert Rev Hematol 2026 Jan 11. CML Patient IDs COSMIC Signature(s) Core Pathway Top Repurposed Drugs 1–4 S3 / S5 HR deficiency, checkpoint failure PARP inhibitors (olaparib), CDK/MDM2 inhibitors 5–7 S1 Epigenetic dysregulation IDH inhibitors (enasidenib), PARP/ATR inhibitors 8–9 S2 Replication stress ATR inhibitors (AZD6738), antimetabolites 10–12 S13 / S18 Oxidative & inflammatory stress JAK inhibitors (ruxolitinib), NAC
No takes yet. Share an insight, caveat, or question.
Iqbal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: